Colin Ross

Colin Ross is a Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia and a Scientist at BC Children’s Hospital and St. Paul’s Hospital. He leads the Ross Laboratory, focusing on pharmacogenomics, gene therapy, and precision medicine to improve drug safety and develop targeted therapeutics for pediatric cancer and genetic diseases.

• Co-founded the Canadian Pharmacogenomics Network for Drug Safety (CPNDS)
• Developed Glybera, the first EMA-approved AAV gene therapy for LPL Deficiency
• Current NIH-funded research on genome editor delivery optimization

His research integrates genomics with clinical pharmacology to identify genetic determinants of adverse drug reactions, particularly in chemotherapy-induced toxicities. Key areas include pharmacogenomics, gene therapy, and genome editing. Recent work emphasizes lipid nanoparticle delivery systems for CRISPR-based therapeutics and predictive models for drug-induced ototoxicity.

Ross has authored over 220 peer-reviewed publications in journals like Nature Genetics, NEJM, and Cell Stem Cell. His h-index of 58 reflects significant impact in pediatric pharmacogenetics and gene therapy. Awards include the Michael Smith Foundation Scholar Award, CIHR New Investigator Award, and multiple journal-specific recognitions.

• Pharmacogenomics of chemotherapy toxicity
• Genome editing for genetic diseases
• Transgenic mouse model development
• Multidisciplinary collaborations across North America

Contact: colin.ross@ubb.ca | LinkedIn | Twitter